US 12,378,323 B2
IgM and IgE heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
Roland Kontermann, Nurtingen (DE); Oliver Seifert, Stuttgart (DE); and Aline Plappert, Stuttgart (DE)
Assigned to UNIVERSITAT STUTTGART, Stuttgart (DE)
Filed by UNIVERSITÄT STUTTGART, Stuttgart (DE)
Filed on Nov. 9, 2020, as Appl. No. 17/092,423.
Application 17/092,423 is a continuation of application No. 15/645,892, filed on Jul. 10, 2017, granted, now 10,875,928.
Application 15/645,892 is a continuation of application No. 14/391,930, abandoned, previously published as PCT/EP2013/001126, filed on Apr. 16, 2013.
Claims priority of application No. PCT/EP2012/056938 (WO), filed on Apr. 16, 2012.
Prior Publication US 2021/0139606 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); A61K 39/395 (2006.01); C07K 14/435 (2006.01); C07K 14/52 (2006.01); C07K 14/525 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 39/3955 (2013.01); C07K 14/435 (2013.01); C07K 14/52 (2013.01); C07K 14/525 (2013.01); C07K 16/2863 (2013.01); C07K 16/468 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/524 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2319/30 (2013.01)] 25 Claims
 
1. A polypeptide comprising a heavy chain domain 2 (HD2) from IgM and at least one pharmaceutically active moiety, under the proviso that the pharmaceutically active moiety is not a Fab or Fc fragment from IgM or IgE, wherein the HD2 domain from IgM comprises an amino acid sequence having at least 99% identity to the amino acid sequence of SEQ ID NO: 1 or a dimerizing variant thereof;
wherein the polypeptide does not comprise heavy chain constant domain CH3 of IgM;
and wherein the pharmaceutically active moiety is an antibody or antigen binding fragment thereof, a ligand, a cytokine, a receptor, or a tumor marker.